Dr. Timos Papagatsias’ Post

Thoughts on this? >> Allogene's $110M offering; Apellis refinances >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #biotech #productmarketing #healthcare

🚀 #BiotechTrends Mesoblast Ltd witnesses a dramatic share price surge—up 45.5%—post promising FDA discussions regarding their lead product, remestemcel-L. The #FDA has indicated that clinical data is sufficient to support a Biologics License Application, a significant step forward for the company's treatment for inflammatory diseases. 👩🔬💡 Investor confidence has rocketed, peaking share prices at 96 cents from 33 cents in just days. This climbing momentum marks investor optimism and forecasts a potentially vibrant market future for Mesoblast. While a recent pullback in share price has occurred, the market keenly awaits the official filing with the FDA. Mesoblast's outlook remains a subject of intrigue as stakeholders look towards a potential transformative impact on the company's market value and treatment contributions. 🌟📈 Read the full analysis and insight on how Mesoblast is shaping up to potentially revolutionize the biotech landscape: https://lnkd.in/gmQygRYE #Mesoblast #StockMarket #HealthcareInnovation #Investment #Biotechnology

February was a month full of exciting news, from outstanding performance of NurExone Biologic (TSXV: NRX) (FSE: J90) to publication of findings that exosomes can carry endocannaninoids. UPDATE: Due to the time difference, the original version of this analysis did not include the latest financial results from Capricor Therapeutics. The PDF has now been updated to reflect this. #extracellularvesicles #exosomes #biotech #pharma #therapies #drugdiscovery #lifescienceindustry #investing #biotechinnovation #investing #BiotechInnovation, #HealthcareSolutions, #StartupGrowth, #MedicalTechnology, #TherapeuticAdvances, #BiomedicalResearch, #InvestInHealth, #LifeSciencesVC, #BiotechFunding, #DisruptiveMedTech

Thoughts on this? >> Another ADC biotech reels in big bucks as Mark Alles’ TORL nabs $158M >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #healthcare #biotech #productmarketing #pharma

Thoughts on this? >> Another ADC biotech reels in big bucks as Mark Alles’ TORL nabs $158M >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #productmarketing #pharmaceutical #biotech #pharma

Thoughts on this? >> A once-public psychedelic biotech reemerges with $103M from MPM and Novo Holdings >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #productmarketing #pharmaceutical #biotech #healthcare

Thoughts on this? >> Exclusive: Nocion raises $62M for different approach to chronic cough than Merck, GSK >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #healthcare #pharmaceutical #biotech #pharma

Heads up ⬆️ #DCAT week is in 2 weeks! Connect with our Bioequivalence Expert Mo H. to meet up in the big 🍎 Want to understand BioPharma Services Inc. capabilities in supporting your next drug development project? Shoot Mo a connection invite! BioPharma Services Inc. specializes in #Phase1 clinical trials, #bioequivalence, #bioavailability, First-in-Human and Human Abuse Potential Studies (#HAP). Let our world-renowned #Pharmacokinetics team execute your next clinical trial with confidence. . . . #biopharma #clinicalresearch #clinicalstudies #clinicaltrials #bioanalytics #dcatweek #generics

Agomab draws $100M for fibrosis pipeline, adding to drumbeat of nine-figure Series C rounds >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #productmarketing #pharmaceutical #pharma #biotech

Dr. Terri Gaskell, CTO of Rinri Therapeutics, shares her insights on developing and manufacturing a PSC therapeutic at IMAPAC Biomanufacturing 5.0 conference today in London. Her advice? Begin with the end in mind. Don't just focus on what is acceptable in a First-In-Human (FIH) trial, but consider what will likely change to generate a commercial product. Dr. Gaskell emphasizes the importance of collecting everything while developing your manufacturing process. This will facilitate retrospective analysis and help you identify areas for improvement. Additionally, it's crucial to know the sensitivity, robustness, and limitations of your tools. Rely on them only as much as justified. Bank sufficient material to validate your assays if justified in risk assessment. Remember, developing a successful commercial product requires thoughtful planning and attention to detail. Thank you, Terri, for sharing your valuable insights. #productdevelopment #manufacturingprocess #commercialproduct #biotech #advancedtherapies #PSC